Recalls & Warnings March 09, 2020 FDA Warns Sellers of Essential Oils, Colloidal Silver & Teas Promoted to Treat Coronavirus On March 9, 2020, the FDA and FTC announced they have issued joint warning letters to seven companies for selling products such as essential oils, teas and colloidal silver with unsupported claims that they can treat coronavirus (COVID-19)
For patients with polypharmacy, comorbid endocrine disease, or family history of thyroid malignancy, in-depth clinical evaluation is essential before GLP-1 initiation
Supplementation with Lactobacillus pentosus strain S-PT84 and vitamin B mixture enhances natural killer cell activity in healthy humans
However, there is no clear segmental split in financials, so its unclear how much comes from high-margin vs
Similar content being viewed by others Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have emerged as a transformative class of therapeutics that promote weight loss, improve glycemic control, and provide systemic benefits across multiple organ systems 1,2,3,4
Clinical data, including results from the March 2026 Phase 3 TRANSCEND-T2D-1 trial, suggests that retatrutide exhibits properties relevant to weight regulation and glycemic modulation in research models
